Last reviewed · How we verify

NCT06005558

Low Dose Versus High Dose Methylene Blue in Septic Patients

Completed Phase 2, PHASE3 Last updated 5 July 2024
What this trial tests

Phase 2, PHASE3 trial testing Normal saline in Septic Shock in 90 participants. Completed in 15 May 2024.

Timeline
1 August 2023
Primary endpoint
29 April 2024
15 May 2024

Quick facts

Lead sponsorNational Cancer Institute, Egypt
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment90
Start date1 August 2023
Primary completion29 April 2024
Estimated completion15 May 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

National Cancer Institute, Egypt

Who can join

Adults 18 to 65, any sex, with Septic Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of this study is to examine the various effects of continuous methylene blue infusion in septic cancer patients and to compare it with the traditional infusion of noradrenaline in such patients .

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Comparative study between high and low dose methylene blue infusion in septic cancer patients: a randomized, blinded, controlled study.
    Shaker EH, Soliman AM, Bedewy AAE, Elrawas MM. · · 2025 · cited 6× · PMID 39780053 · DOI 10.1186/s12871-024-02792-3

Verify or expand the search:

Other trials of Normal saline

Trials testing the same drug.

Other recruiting trials for Septic Shock

Currently open trials in the same condition.

Other National Cancer Institute, Egypt trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06005558.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing